Literature DB >> 30319981

Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2018        PMID： 30319981      PMCID： PMC6170913          DOI： 10.1159/000492533

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  17 in total

1.  Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Authors:  Maxime Ronot; Mohamed Bouattour; Johanna Wassermann; Onorina Bruno; Chantal Dreyer; Béatrice Larroque; Laurent Castera; Valérie Vilgrain; Jacques Belghiti; Eric Raymond; Sandrine Faivre
Journal:  Oncologist       Date:  2014-03-20

2.  mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.

Authors:  Tim Meyer; Daniel H Palmer; Ann-Lii Cheng; Julia Hocke; Arsène-Bienvenu Loembé; Chia-Jui Yen
Journal:  Liver Int       Date:  2017-02-02       Impact factor: 5.828

Review 3.  General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Masayuki Kitano; Toshiharu Sakurai; Naoshi Nishida
Journal:  Dig Dis       Date:  2015-10-21       Impact factor: 2.404

4.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

Review 5.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

6.  Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.

Authors:  Tadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Mashiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
Journal:  Dig Dis       Date:  2014-10-29       Impact factor: 2.404

7.  Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

Authors:  Tim Meyer; Richard Fox; Yuk Ting Ma; Paul J Ross; Martin W James; Richard Sturgess; Clive Stubbs; Deborah D Stocken; Lucy Wall; Anthony Watkinson; Nigel Hacking; T R Jeffry Evans; Peter Collins; Richard A Hubner; David Cunningham; John Neil Primrose; Philip J Johnson; Daniel H Palmer
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-06-23

8.  Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.

Authors:  Masatoshi Kudo; Guohong Han; Richard S Finn; Ronnie T P Poon; Jean-Frederic Blanc; Lunan Yan; Jijin Yang; Ligong Lu; Won-Young Tak; Xiaoping Yu; Joon-Hyeok Lee; Shi-Ming Lin; Changping Wu; Tawesak Tanwandee; Guoliang Shao; Ian B Walters; Christine Dela Cruz; Valerie Poulart; Jian-Hua Wang
Journal:  Hepatology       Date:  2014-09-29       Impact factor: 17.425

9.  Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Osamu Yokosuka; Sadahisa Ogasawara; Shuntaro Obi; Namiki Izumi; Hiroshi Aikata; Hiroaki Nagano; Etsuro Hatano; Yutaka Sasaki; Keisuke Hino; Takashi Kumada; Kazuhide Yamamoto; Yasuharu Imai; Shouta Iwadou; Chikara Ogawa; Takuji Okusaka; Fumihiko Kanai; Kohei Akazawa; Ken-Ichi Yoshimura; Philip Johnson; Yasuaki Arai
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-04-07

10.  Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.

Authors:  Sadahisa Ogasawara; Tetsuhiro Chiba; Yoshihiko Ooka; Naoya Kanogawa; Tenyu Motoyama; Eiichiro Suzuki; Akinobu Tawada; Fumihiko Kanai; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  Oncology       Date:  2014-09-06       Impact factor: 2.935
View more
  24 in total

1.  Pembrolizumab for the Treatment of Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-04-29       Impact factor: 11.740

2.  Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-10-26       Impact factor: 11.740

3.  A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.

Authors:  Masatoshi Kudo; Kwang-Hyub Han; Sheng-Long Ye; Jian Zhou; Yi-Hsiang Huang; Shi-Ming Lin; Chung-Kwe Wang; Masafumi Ikeda; Stephen Lam Chan; Su Pin Choo; Shiro Miyayama; Ann Lii Cheng
Journal:  Liver Cancer       Date:  2020-05-13       Impact factor: 11.740

4.  A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-09-18       Impact factor: 11.740

Review 5.  Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-11-17       Impact factor: 11.740

Review 6.  Implications of Immunotherapy in Hepatobiliary Tumors.

Authors:  Aline Gottlieb; Jan Best; Ali Canbay
Journal:  Visc Med       Date:  2019-02-08

7.  Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies.

Authors:  Kazuya Kariyama; Kazuhiro Nouso; Akiko Wakuta; Ayano Oonishi; Hidenori Toyoda; Toshifumi Tada; Atsushi Hiraoka; Kunihiko Tsuji; Ei Itobayashi; Toru Ishikawa; Koichi Takaguchi; Akemi Tsutsui; Noritomo Shimada; Takashi Kumada
Journal:  Liver Cancer       Date:  2019-10-22       Impact factor: 11.740

8.  Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.

Authors:  Haijing Deng; Anna Kan; Ning Lyu; Luwen Mu; Yi Han; Longzhong Liu; Yanyu Zhang; Youfa Duan; Shuangye Liao; Shaolong Li; Qiankun Xie; Tianxiao Gao; Yanrong Li; Zhenfeng Zhang; Ming Zhao
Journal:  Liver Cancer       Date:  2020-02-25       Impact factor: 11.740

9.  Feasibility and Techniques of Securing 3D-Safety Margin in Superselective Transarterial Chemoembolization to Improve Local Tumor Control for Small Hepatocellular Carcinoma: An Intend-to-Treat Analysis.

Authors:  Ching Charoenvisal; Toshihiro Tanaka; Hideyuki Nishiofuku; Hiroshi Anai; Takeshi Sato; Takeshi Matsumoto; Nagaaki Marugami; Kimihiko Kichikawa
Journal:  Liver Cancer       Date:  2021-01-12       Impact factor: 11.740

10.  Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.

Authors:  Haijing Deng; Anna Kan; Ning Lyu; Meng He; Xin Huang; Shuang Qiao; Shaolong Li; Wenhua Lu; Qiankun Xie; Huiming Chen; Jinfa Lai; Qifeng Chen; Xiongying Jiang; Shousheng Liu; Zhenfeng Zhang; Ming Zhao
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.